Hackensack (N.J.) University Medical Center joined a trial to test the benefits of transcarotid artery revascularization in patients with an average surgical risk.
TCAR is a minimally invasive procedure that allows surgeons to treat blockages inside the carotid arteries with a stent through a small incision in the patient's neck, according to an April 4 hospital release.
"Initially, TCAR was only approved for patients with carotid artery disease who were at high risk of experiencing surgical complications due to age, other medical conditions, or complex anatomy," said David O'Connor, MD, director of vascular research at Hackensack University Medical Center. "Through the ROADSTER 3 trial, we are looking at the benefits of TCAR for patients with a standard surgical risk with the goal of expanding our ability to offer this procedure to a majority of patients with carotid artery disease."
Hackensack is the only site in New Jersey to participate in ROADSTER 3.